Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma During Pembrolizumab Therapy: A Case Report

Komugi Okeya; Yukio Kawagishi; Emiri Muranaka; Toshihide Izumida; Hiroshi Tsuji; Shinichi Takeda

doi:10.2169/internalmedicine.2892-19

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma During Pembrolizumab Therapy: A Case Report

Komugi Okeya, Yukio Kawagishi, Emiri Muranaka, Toshihide Izumida, Hiroshi Tsuji, Shinichi Takeda

著者情報

キーワード: immune checkpoint inhibitors, pembrolizumab, hyperprogressive disease, transformation, small-cell carcinoma

ジャーナルオープンアクセス早期公開

論文ID: 2892-19

DOI https://doi.org/10.2169/internalmedicine.2892-19

この記事には本公開記事があります。

The final version of this article is now available: Vol. 58 (2019), No. 22 pp. 3295-3298

詳細

抄録

Hyperprogressive disease (HPD) is a paradoxical phenomenon involving the acceleration of tumor progression after treatment with immune checkpoint inhibitors (ICIs). A 66-year-old male smoker with advanced lung adenocarcinoma started pembrolizumab for progressive disease following first-line chemotherapy. He developed HPD after two cycles, and a re-biopsy revealed transformation to small-cell carcinoma. He subsequently underwent two lines of chemotherapy for small-cell carcinoma until progression and ultimately died. Transformation to small-cell carcinoma may be a cause of HPD during ICI therapy. The possibility of pathological transformation should be considered in cases of HPD with resistance to ICI therapy.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）